Safety and Efficacy of Dupilumab for the Treatment of Hospitalized Patients with

2 Moderate to Severe COVID 19: A Phase IIa Trial

- 4 Jennifer Sasson¹, Alexandra N. Donlan^{1,2}, Jennie Z. Ma³, Heather Haughey⁴, Rachael Coleman¹, Uma
- Nayak⁵, Amy J. Mathers^{1,6}, Patrick E. H. Jackson¹, Scott K. Heysell¹, Jeffrey M. Sturek⁴, William A. Petri,
- 6 Jr^{1,2,6*}

1

3

7

- 8 ¹Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia Health System,
- 9 Charlottesville, VA, USA:
- 10 ²Department of Microbiology, Immunology and Cancer Biology, University of Virginia School of Medicine, Charlottesville, VA, USA;
- 11 ³Department of Public Health Sciences, University of Virginia School of Medicine, Charlottesville, Virginia, USA;
- ⁴Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Virginia Health System, Charlottesville,
- 13 VA, USA;

- 14 ⁵Center for Public Health Genomics and Department of Public Health Sciences, University of Virginia School of Medicine,
- 15 Charlottesville, VA, USA:
- ⁶Department of Pathology, University of Virginia Health System, Charlottesville, VA, USA
- 18 *Corresponding author: William A. Petri Jr. University of Virginia, 345 Crispell Drive, Charlottesville Virginia 22908-1340, USA.
- 19 Email: wap3g@virginia.edu; Phone: 434.924.5621. ORCID ID 0000-0002-7268-1218

ABSTRACT Background: A profound need remains to develop further therapeutics for treatment of those hospitalized with COVID-19 to prevent respiratory decline or death. Based on data implicating the type 2 cytokine interleukin (IL)-13 as a significant factor leading to critical COVID-19, this trial was designed to assess the safety and efficacy of dupilumab, a monoclonal antibody that blocks IL-13 and IL-4 signaling, in those hospitalized with COVID-19. Methods: We conducted a phase IIa randomized double-blind placebo-controlled trial to assess the safety and efficacy of dupilumab plus standard of care versus placebo plus standard of care in mitigating respiratory failure and death in those hospitalized with COVID-19. Subjects were followed prospectively for 60 days, with collection of clinical outcomes, adverse events and immunologic biomarkers at multiple time points throughout the study period. The primary endpoint was the proportion of patients alive and free of invasive mechanical ventilation at 28 days analyzed in logistic regression. Results: Forty eligible subjects were enrolled from June 23, 2021 through November 11, 2021. There was no difference in adverse events nor in proportion of patients alive and free of mechanical ventilation at day 28 between study treatment groups. However, for the secondary endpoint of mortality at day 60, subjects randomized to dupilumab had a higher survival rate: 89.5% of subjects in the dupilumab group were alive compared to 76.2% in the placebo group (adjusted HR 0.05, 95% CI: 0.0- 0.72, p=0.03). There was a trend toward reduction in ICU admission in the dupilumab group compared to the placebo group (33.3% vs 66.7%; adjusted HR 0.44, 95% CI: 0.09-2.09, p=0.30). Lastly, we saw downstream evidence of IL-4 and IL-13 signaling blockade through analysis of immune biomarkers at multiple study time points. Conclusions: Dupilumab was well tolerated and improved 60-day survival in patients hospitalized with moderate to severe COVID-19. Blockade of type 2 immunity offers promise as a novel treatment for COVID-19.

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

INTRODUCTION:

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

With in-hospital mortality of 10-26%^{1,2} and the ongoing threats of new SARS-CoV-2 variants, there remains a substantial need for additional therapeutics for those hospitalized with COVID-19. Current therapies have demonstrated variable and/or modest benefit. For example, the RECOVERY trial showed a mortality reduction from 26% to only 23% with dexamethasone use in those hospitalized with COVID-19 respiratory failure, with the greatest mortality benefit seen in those requiring mechanical ventilation at randomization³. Clinical trials for remdesivir, an antiviral nucleoside analog, have produced variable results, with the ACTT-1 trial demonstrating a 5 day reduction in clinical recovery time in those on supplemental oxygen⁴. Randomized controlled trials investigating interleukin (IL)-6 inhibitors have shown conflicting results, with some indicating a mortality benefit in those within 24 hours of intensive care unit (ICU) admission and others showing no difference in clinical outcomes between study groups^{5,6}. Janus kinase inhibitors initially showed only a 1 day improvement in clinical recovery time when combined with remdesivir, with later trials since showing reduced mortality from 13% to 8% when combined with usual care in those requiring hospitalization and at least 1 elevated inflammatory marker^{7,8}. Findings from these studies suggest a need for improvement in treatment of those admitted with COVID-19 pneumonia. We have discovered that COVID-19 patients with high plasma IL-13 levels have a significantly greater risk of needing mechanical ventilation⁹. IL-13, which signals through the receptor IL-4Ra along with the closely related cytokine IL-4, is involved in eosinophilic inflammation, mucous secretion, goblet cell metaplasia and fibrosis, and has been regularly implicated in airway hyperresponsiveness and atopic disease¹⁰. We additionally found that neutralization of IL-13 in K18-hACE2 C57BI/6J mice protected the animals from severe infection with SARS-CoV-2, as evidenced by reduced clinical score, weight loss and mortality⁹. The association of IL-13 along with other effectors of type 2 immunity with respiratory failure from COVID-19 has also been

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

demonstrated in other observation studies 11,12. These findings established mechanistic and biologic plausibility for IL-13 as a driver of pulmonary injury in COVID-19. There are medications available to block IL-13 signaling: dupilumab, an anti-IL-4Rα monoclonal antibody, was approved for treatment of moderate to severe atopic dermatitis by the FDA in 2017. It reduces clinical severity in patients with allergic diseases including atopic dermatitis. asthma and chronic rhinosinusitis¹³. The original clinical trials demonstrated minimal adverse events with dupilumab use, favoring it as a steroid sparing therapy in atopic disease 14,15. Post hoc analysis of initial studies saw reduced incidence of respiratory viral infections with its use¹⁶. Dupilumab use was associated with greater survival from COVID-19 in retrospective analysis: using the TriNetX international electronic medical record (EMR) database, we previously identified a cohort of 350,004 patients with COVID-19, of whom 81 had been prescribed dupilumab prior to their COVID-19 diagnosis⁹. Patients on dupilumab had a 12.3% absolute risk reduction in mortality compared to a propensity score matched sub cohort of 81 patients with COVID-19 not on dupilumab but with atopic diseases for which dupilumab is routinely used⁹. Dupilumab has since been shown to reduce symptom severity and improve clinical outcomes in other observational studies utilizing large patient databases^{17,18}. The association of IL-13 with COVID-19 respiratory failure, the demonstration of survival benefit with IL-13 blockade in a mouse model and the retrospective EMR analysis showing reduced COVID-19 mortality in those receiving dupilumab for atopic disease, provided significant evidence for further exploration of dupilumab use for treatment of COVID-19. This along with the safety of dupilumab and the potential for a targeted approach to therapy led to the design of a clinical trial to test its use in those hospitalized with COVID-19.

METHODS

Design

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

This was a randomized, double-blind, placebo-controlled trial designed to assess the safety and efficacy of dupilumab use in 40 hospitalized patients with moderate to severe COVID-19 infection. It was approved by the University of Virginia Institutional Review Board (IRB) in June 2021 (NCT04920916). Eligible subjects were enrolled and randomized at a 1:1 ratio to receive either dupilumab or placebo, stratifying on disease severity measured by an oxygen requirement of ≤ 15 L/min or > 15 L/min by nasal cannula. Included were those over the age of 18 who were hospitalized with a positive reverse transcription polymerase chain reaction test (RT-PCR) for SARS-CoV-2 within the last 14 days and evidence of moderate to severe COVID-19 as defined by National Institutes of Health (NIH) COVID-19 Severity Categorization 19. Patients requiring mechanical ventilation at the time of enrollment were excluded. Both arms received standard of care management per current NIH COVID-19 treatment guidelines. including dexamethasone and remdesivir as deemed appropriate by their primary provider¹⁹. Subjects received a loading dose of dupilumab (600 mg, given as two 300 mg subcutaneous injections) or placebo on day 0 with additional maintenance doses of 300 mg or placebo given on days 14 and 28 if the subject remained hospitalized and receiving active care²⁰. Subjects were followed prospectively for 60 days.

Outcomes

The primary outcome of the study was the proportion of patients alive and free of invasive mechanical ventilation at day 28. Safety outcomes were assessed via determination of the cumulative incidence of adverse events, including those previously reported to occur with dupilumab use (i.e., injection site reactions, eye/eyelid inflammation, conjunctivitis, herpes viral infection, eosinophilia)²⁰. Additional clinical endpoints included all-cause mortality at day 28 and 60, proportion of patients alive and free of invasive mechanical ventilation at 60 days, hospital

length of stay (LOS), ICU LOS, change in 8-point ordinal score and change in partial pressure of oxygen (PaO₂) or oxygen saturation (SaO₂) to fraction of inspired oxygen (FiO₂) ratio. Plasma inflammatory markers, including C reactive protein (CRP), ferritin and a 47-plex cytokine panel were measured at various time points during the study. Additional type 2 inflammatory markers including TARC (CCL17), YKL40, eotaxin 3 (CCL26), arginase1 (Arg1), hyaluronan, soluble ST2 and total serum immunoglobulin E (IgE) were also measured. Ferritin, CRP and IgE levels were measured at the University of Virginia Clinical Laboratories while other biomarkers were measured by multiplex immunoassays or ELISAs depending on the analyte. Day 0 nasopharyngeal (NP) swabs obtained for assessment of SARS-CoV-2 RNA positivity via RT-PCR underwent genomic sequencing to determine the SARS-CoV-2 lineage²¹.

Statistical Analysis

COVID-19 hospitalization data from UVA between March 2020 and April 2021 showed that 79.5% of COVID-19 inpatients were alive and free of mechanical ventilation at 28 days under usual care. With a pre-selected sample size of 40 patients and alpha=0.1 (one sided), we would be able to detect a difference of 17.7% in the proportion of subjects alive and free of mechanical ventilation at 28 days with 75% power.

Primary and secondary outcomes were analyzed under the intention-to-treat (ITT) principle. Safety outcomes were analyzed in the as treated population, including subjects who were enrolled and received at least one dose of study drug. Demographics, clinical and safety outcomes were analyzed initially with the Chi-square or Fisher's exact tests for categorical measures and two-sample t-test or Wilcoxon rank sum for continuous measures, after assessment of normality. Treatment differences in ventilator free survival proportions were analyzed via logistic regression. Mortality differences were evaluated by the log-rank test and further in the Cox regression for time to death outcome. Baseline patient characteristics and

known risk factors for severe disease in COVID-19, including age, sex, body mass index (BMI), comorbidities and COVID-19 vaccination status, were adjusted in regression models if initial analyses discovered imbalance in group characteristics²². Differences in the biomarkers between treatment groups were analyzed exploratively by t-test or Wilcoxon rank sum testing at each time point.

As an exploratory analysis, we included mechanical ventilation as a time varying variable in the Cox regression for further investigation of its influence on survivability. This allowed us to account for the significant change in mortality risk between pre- and post-intubation when a patient was placed on mechanical ventilation. We additionally tested differences in the likelihood of ICU admission between the two groups by the log-rank test.

RESULTS

Patient and Virus Characteristics

Forty patients were enrolled from June 23, 2021 through November 11, 2021 (Fig S1). The groups were well matched with regard to age, BMI, race, ethnicity, comorbidities, vaccination status and days from COVID-19 symptom onset to enrollment (Table 1). Patients in the placebo arm were more likely to be male compared to the dupilumab arm (76.2% vs. 36.8%). There were no significant differences in non-study COVID-19 therapies received between the treatment groups (Table 1). Of those NP samples available for SARS-CoV-2 sequencing, 30 of 31 (96.8%) subjects had the delta variant and one subject in the placebo group had the iota variant (Table S1).

		Placebo (n=21)	Dupilumab (n=19)
∧ge		63.0 (23.0)	59 (26.0)
Sex			
	Male	16 (76 2%)	7 (36-8%)
BMI		32.3 (10.1)	33.6 (14.9)
□thnicity			
	Hispanic	3 (14.3%)	3 (15.8%)
Race			
	White	14 (66.7%)	13 (68.4%)
	Black	6 (28.6%)	4 (21.1%)
	Asian	0 (0.0%)	1 (5.3%)
	Other	1 (4.8%)	1 (5.3%)
Comorbiditi	ies		
	Obesity	15 (71.4%)	14 (73.7%)
	Chronic Kidney Disease	7 (33.3%)	3 (15.3%)
	Asthma	4 (19.1%)	4 (21.1%)
	Respiratory Disease (COPD, emphysema)	3 (14 3%)	2 (10.5%)
	Diabetes	8 (38.1%)	7 (36.8%)
	Coronary Artery Disease	6 (28.6%)	3 (15.8%)
	Cardiac Valvular Disease	3 (14 3%)	2 (10.5%)
	Hypertension	10 (47.6%)	8 (42.1%)
	Congestive Heart Failure	5 (23.8%)	2 (10.5%)
	Cardiac Arrythmia	4 (19.1%)	1 (5.3%)
	Depression or psychotic disorder	3 (14.3%)	8 (12.1%)
	Malignancy	4 (19.1%)	3 (15.8%)
	Autoimmune disease	2 (9.5%)	2 (10.5%)
	Organ or stem cell transplant recipient	3 (14.3%)	1 (5.3%)
	Other immune deficiency	1 (4.8%)	0 (0.0%)
Smoking H	istory		
	Never	12 (57.1%)	15 (79.0%)
	Current	3 (14.3%)	0 (0.0%)
	Past	6 (28.6%)	4 (21.1%)
Days from	symptom onset to study treatment	8 0 (4 0)	/ 0 (5 0)
Received C	OVID 19 vaccine		
	Moderna	4 (19.1%)	1 (5.3%)
	Ptizer	5 (23 8%)	4 (21 1%)
	J&J	0 (0.0%)	2 (10.5%)
	None	12 (57.1%)	12 (63.2%)
Other COV	ID-19 therapeutics received		
	Steroids	20 (95.2%)	19 (100%)
	Remdesivir	18 (85.7%)	16 (84.2%)
	IL-6 inhibitor	0 (0.0%)	0 (0.0%)
	Janus kinase inhibitor	4 (19.1%)	1 (5.3%)
	Monoclonal antibodies	3 (14.3%)	2 (10.5%)

Table 1: Patient characteristics. Continuous variables expressed as median (interquartile range). Categorical variables expressed as total n (percentage). Age expressed in years. Body Mass Index (BMI, kg/m²), Chronic Obstructive Pulmonary Disease (COPD), Johnson and Johnson (J&J).

Safety

There were no significant differences in cumulative adverse events observed between the treatment groups (Table 2). In the dupilumab group, five subjects developed asymptomatic eosinophilia compared to one subject in the placebo group (Fisher's exact p=0.09). There were no clinical consequences, including dermatologic, gastrointestinal, pulmonary, cardiac or neurologic, attributed to the peripheral eosinophilia seen in these subjects.

	Placebo (n=21)	Dupilumab (n=19)	
Injection site reactions	0 (0.0%)	0 (0.0%)	
Conjunctivitis	2 (9.5%)	0 (0.0%)	
Bacterial pneumonia	1 (4.8%)	2 (10.5%)	
Herpes viral infection	0 (0.0%)	0 (0.0%)	
Eosinophilia*	1 (4.8%)	5 (26.3%)	
Hyper eosinophilic syndrome	0 (0.0%)	0 (0.0%)	
Other infections	2 (9.5%)	4 (21.1%)	
Cumulative	6	11	

Table 2: Adverse events observed throughout the study period by treatment group. Other infections included *Clostridioides difficile* infection (1), bacteremia (2), urinary tract infections (2) and oral candidiasis (1). Categorical variables expressed as total n (percentage). Eosinophilia was defined as an absolute eosinophil count >0.6 k/uL at \geq 1 measurement throughout the study period. *Difference between treatment groups was not statistically significant with Fischer's exact p=0.09.

Clinical Efficacy

There was no significant difference in the primary endpoint of proportion of patients alive and free of mechanical ventilation at day 28 between the two groups (Table 3). However, by secondary endpoint at 60 days, 89.5% of subjects in the dupilumab group were alive compared to 76.2% for the placebo group as no patients remained on mechanical ventilation by day 60 in either group (Table 3). After adjustment for sex and mechanical ventilation as a time varying predictor, the risk of death over 60-day follow-up period was significantly lower in dupilumab group compared to placebo (Table 3; Fig 1).

	Placebo (n=21)	Dupilumab (n=19)	OR (95% CI) or HR (95% CI)	P value
Proportion of patients alive and free of mechanical	18 (85.7%)	15 (78.9%)	Unadjusted OR: 1.60 (0.31, 8.30)	0.57
ventilation by day 28			Adjusted OR: 2.45 (0.40, 15.10)	0.34
Proportion of patients alive and free of mechanical	16 (76.2%)	17 (89.5%)	Unadjusted OR: 0.38 (0.06, 2.22)	0.28
ventilation by day 60			Adjusted OR: 0.44 (0.07, 2.96)	0.40
Mortality by day 28	3 (14.3%)	1 (5.3%)	Unadjusted HR: 0.35 (0.04, 3.32)	0.36
			Adjusted HR: 0.06 (0.00, 1.59)	0.09
Mortality by day 60	5 (23.8%)	2 (10.5%)	Unadjusted HR: 0.40 (0.08, 2.05)	0.27
			Adjusted HR: 0.05 (0.00, 0.72)	0.03

Table 3: Primary and key secondary endpoints by treatment group. Primary endpoint was ventilator free survival by day 28. Secondary endpoints were ventilator free survival by day 60, mortality by day 60 and mortality by day 28. Proportions are listed as total n (%). The differences in the ventilator free survival proportions were evaluated using logistic regression, adjusted for sex. The differences in mortality risk were evaluated in the Cox regression, adjusted for sex and time varying mechanical ventilation.




Figure 1: Kaplan Meier survival curves depicting 60-day mortality between two treatment groups. Dupilumab group is represented by blue line. Placebo group is represented by the orange line. Adjusted p value indicative of adjustment for sex and time varying ventilation in the Cox regression. Patient study visits occurred within an allotted range of exact study days and therefore the number at risk in the table is representative of patient data availability up until those exact days (i.e., if study visit was conducted on day 59 and no event had occurred, then the subject was included in the at-risk pool up until day 59 but not in that for day 60).

Numerically fewer subjects in the dupilumab group required ICU care (33.3%) compared to the placebo group (66.7%) though this difference was not statistically significant (log-rank p=0.23, HR 0.44, CI: 0.09-2.09, p=0.30 adjusted for sex, Fig 2). There was no difference in additional secondary endpoints between the two treatment groups (Table 4, Fig S2, Fig S3).




Figure 2: Kaplan Meier curve depicting need for escalation to ICU over 60-day study period. Patients already admitted to the ICU on day of enrollment (n=7) were excluded from analysis. Dupilumab group is represented by blue line. Placebo group is represented by the orange line. Patient study visits occurred within an allotted range of exact study days and therefore the number at risk in the table is representative of patient data availability up until those exact days (i.e., if study visit was conducted on day 59 and no event had occurred, then the subject was included in the at-risk pool up until day 59 but not in that for day 60).

Biomarker Analysis

In both treatment groups, CRP, ferritin and IgE levels declined in the first two weeks with no significant difference in the change in measures from day 0 to 14 between groups (Fig S4). When looking at the change in absolute cell counts over time, there was an increase in eosinophils by day 14 in the dupilumab group compared to the placebo group (p=0.01 by

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

Wilcoxon rank sum, Fig S5). Analysis of patient cytokine, chemokine and growth factors in serum at various study time points showed a decreased monocyte chemoattractant protein-1 (MCP-1) at day 7 in the dupilumab treatment group compared to placebo (p=0.04 by Wilcoxon rank sum, Fig S6). By day 14, there was a larger decrease in eotaxin-3 levels in the dupilumab group compared to the placebo (p=0.08 by Wilcoxon rank sum, Fig S6). Additionally, there was a trend towards decreased levels of YKL40 in the dupilumab group compared to the placebo by day 14 (p=0.26 by Wilcoxon rank sum, Fig S6). **DISCUSSION** In this randomized double-blind placebo-controlled trial, although there was no difference between study groups regarding the primary endpoint of 28-day ventilator free survival, the secondary endpoint of increased 60-day survival in the dupilumab group was achieved. Additionally, there were no safety signals seen with dupilumab use. The overall mortality of subjects in this study had a trend toward more severe disease. ICU mortality was 20% in the dupilumab group versus 36% in placebo, and ventilator mortality was 50% in the dupilumab group compared to 100% in placebo. Severity of illness seen in our study reflected that enrollment occurred during the delta surge and that the majority of those enrolled were unvaccinated, consistent with national data at the time²³. For example, the National Hospital Care Survey (NHCS) data from the US Centers for Disease Control and Prevention (CDC), showed 11.9-13.1% in-hospital mortality in select hospitals throughout the United States during the month of August 2021 with ventilatory mortality rates ranging from 47.9%-74.1%, a time period during which this study enrolled subjects²⁴. The detection of survival and mechanical ventilation differences at 60 days rather than at 28 days is consistent with reports of immunologic dysfunction from COVID-19 extending out to 8

months for mild to moderate COVID-19, with deaths from severe COVID-19 occurring out to 12 months^{25,26}. Although the small size of our study limits broad conclusions about the mortality benefit of dupilumab, these findings combined support a late clinical benefit of blockade of a type 2 immune process in COVID-19. The response to dupilumab in asthma is also protracted with improvements in FEV1 first being observed 2 weeks after initiation of treatment²⁷. Thus, the time to clinical effect of dupilumab in the acute COVID-19 setting may have limited our ability to see early clinical differences between the treatment groups. For example, subjects in our study who ultimately required mechanical ventilation did so within the first 8 days of the study, some within 1-2 days of enrollment, during a time in which drug concentration may have been lower, particularly in the context of a rapidly evolving clinical process.

Although biomarker trends seen in both groups were likely influenced by the steroids that almost all subjects received, we did see a reduction of the Type 2 immune markers YKL40 and eotaxin-3 in the dupilumab arm when compared to the placebo arm, indicative of the IL-4Rα blockade with inhibition of downstream mediators of the type 2 immune response. Increased peripheral eosinophil counts in the dupilumab group occurred by day 14, consistent with previous observations of dupilumab use in patients with atopic disease, likely due to decreased eosinophil uptake in tissue^{27,28}. While we did not see IgE decrease at 2 weeks of dupilumab treatment, this is consistent with prior studies showing gradual decline of IgE levels compared to other biomarkers after dupilumab initiation²⁸. Lastly, we saw reduction in MCP-1, a potent chemoattractant molecule of monocytes/macrophages, in the dupilumab group, high levels of which have been associated with COVID-19 disease severity^{29,30}.

The study had several limitations. These included the lack of achievement of the primary endpoint of proportion of patients alive and free of mechanical ventilation at day 28, and the wide confidence intervals in the survival benefit of dupilumab at day 60. Additional limitations

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

included unequal gender distribution between groups, and a higher-than-expected overall mortality rate. The study also had several notable strengths including having as a foundation the preclinical data on the mechanism of disease exacerbation by IL-13 in COVID-19, originality in the study of type 2 immune inhibition, the use of a prospective placebo-controlled randomized and doubleblind design, and demonstration of the safety of dupilumab. Importantly, there was evidence for mortality reduction and reduced ICU escalation with dupilumab use as we had predicted from animal models and retrospective human studies, despite sample size limitations. In light of the ongoing need for additional therapies for COVID-19 associated respiratory failure and the modest clinical benefits seen with other anti-viral and immunotherapies currently being used, the results of this study advance dupilumab as a promising treatment option for those hospitalized with COVID-19. **COMPETING INTERESTS STATEMENT:** The authors have no competing interests to report. **ACKNOWLEDGEMENTS:** We wish to thank the patients who consented to enroll in this study in an effort to help others with COVID-19 and the nursing staff and providers on the COVID-19 units for their assistance with the trial. We thank Jennifer White for IRB protocol preparation, Amy Warren and Lori Elder for IRB protocol preparation and IND preparation/submission and the staff at the investigational drug pharmacy at UVA. We'd also like to thank Mary Young and William Petri and the Biorepository and Tissue Research Facility at UVA who collected, organized and analyzed research samples.

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

FUNDING STATEMENT: This work is supported by grants from the Virginia Biosciences Health Research Corporation, by PBM C19, the Henske Family Foundation, and NIH grants R01 Al124214, T32 Al007496 (AD), T32 DK072922/ TL1 DK132771 (JS), UL1TR003015 and KL2TR003016 (JMS and JZM). **WORKS CITED** Macedo A, Gonçalves N, Febra C. COVID-19 fatality rates in hospitalized patients: 1. systematic review and meta-analysis. Ann Epidemiol. 2021;57:14-21. doi:10.1016/j.annepidem.2021.02.012 Gray WK, Navaratnam A V, Day J, et al. Variability in COVID-19 in-hospital mortality 2. rates between national health service trusts and regions in England: A national observational study for the Getting It Right First Time Programme. EClinicalMedicine. 2021;35:100859. doi:10.1016/j.eclinm.2021.100859 3. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021;384(8):693-704. doi:10.1056/NEJMoa2021436 4. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 — Final Report. N Engl J Med. 2020;383(19):1813-1826. doi:10.1056/NEJMoa2007764 Rosas IO, Bräu N, Waters M, et al. Tocilizumab in Hospitalized Patients with Severe 5. Covid-19 Pneumonia. N Engl J Med. 2021;384(16):1503-1516. doi:10.1056/NEJMoa2028700 Interleukin-6 Receptor Antagonists in Critically III Patients with Covid-19. N Engl J Med. 6. 2021;384(16):1491-1502. doi:10.1056/NEJMoa2100433 Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus Remdesivir for Hospitalized 7. Adults with Covid-19. N Engl J Med. 2021;384(9):795-807. doi:10.1056/nejmoa2031994 8. Marconi VC, Ramanan A V, de Bono S, et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double321 blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med. 2021;19(21):1-322 12. doi:10.1016/s2213-2600(21)00331-3 323 9. Donlan AN, Sutherland TE, Marie C, et al. IL-13 is a driver of COVID-19 severity. JCI 324 Insight. 2021;6(15). doi:10.1172/jci.insight.150107 325 10. Wynn TA. IL-13 effector functions. Annu Rev Immunol. 2003;21:425-456. 326 doi:10.1146/annurev.immunol.21.120601.141142 327 Lucas C, Wong P, Klein J, et al. Longitudinal analyses reveal immunological misfiring in 11. 328 severe COVID-19. Nature. 2020;584(7821):463-469. doi:10.1038/s41586-020-2588-y 329 12. Liang Y, Ge Y, Sun J. IL-33 in COVID-19: friend or foe? Cell Mol Immunol. 330 2021;18(6):1602-1604. doi:10.1038/s41423-021-00685-w 331 13. Thibodeaux Q, Smith MP, Ly K, Beck K, Liao W, Bhutani T. A review of dupilumab in the 332 treatment of atopic diseases. Hum Vaccines Immunother. 2019;15(9):2129-2139. 333 doi:10.1080/21645515.2019.1582403 334 14. Wenzel S, Castro M, Corren J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled 335 336 corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-337 controlled pivotal phase 2b dose-ranging trial. Lancet. 2016;388(10039):31-44. 338 doi:10.1016/S0140-6736(16)30307-5 339 15. Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-340 to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids 341 (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, 342 phase 3 trial. Lancet. 2017;389(10086):2287-2303. doi:10.1016/S0140-6736(17)31191-1 343 Geng B, Bachert C, Busse WW, et al. Respiratory Infections and Anti-Infective 16. 344 Medication Use From Phase 3 Dupilumab Respiratory Studies. J Allergy Clin Immunol 345 *Pract.* 2022;10(3):732-741. doi:10.1016/j.jaip.2021.12.006

Ungar B, Glickman JW, Golant AK, et al. COVID-19 Symptoms Are Attenuated in

346

17.

347 Moderate-to-Severe Atopic Dermatitis Patients Treated with Dupilumab. J Allergy Clin 348 Immunol Pract. 2022;10(1):134-142. doi:10.1016/j.jaip.2021.10.050 349 18. Mahroum N, Damiani G, Watad A, et al. Higher rates of COVID-19 but less severe 350 infections reported for patients on Dupilumab: a Big Data analysis of the World Health 351 Organization VigiBase. Eur Rev Med Pharmacol Sci. 2021;25(18):5865-5870. 352 doi:10.26355/eurrev 202109 26808 353 19. National Institutes of Health (NIH). Coronavirus Disease 2019 (COVID-19) Treatment 354 Guidelines, 2020;2019;130, https://covid19treatmentauidelines.nih.gov 355 20. Food and Drug Administration (FDA). Dupixent package insert. Published online 2020. 356 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761055s014lbl.pdf 357 21. Rambaut A, Holmes EC, O'Toole Á, et al. A dynamic nomenclature proposal for SARS-358 CoV-2 lineages to assist genomic epidemiology. Nat Microbiol. 2020;5(11):1403-1407. 359 doi:10.1038/s41564-020-0770-5 22. 360 Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related 361 death using OpenSAFELY. Nature. 2020;584(7821):430-436. doi:10.1038/s41586-020-362 2521-4 363 23. Centers for Disease Control and Prevention (CDC). Rates of laboratory-confirmed 364 COVID-19 hospitalizations by vaccination status. https://covid.cdc.gov/covid-data-365 tracker/#covidnet-hospitalizations-vaccination 366 24. Center for Disease Control and Prevention (CDC). In-hospital Mortality Among Hospital 367 Confirmed COVID-19 Encounters by Week From Selected Hospitals. 368 https://www.cdc.gov/nchs/covid19/nhcs/hospital-mortality-by-week.htm 369 25. Phetsouphanh C, Darley DR, Wilson DB, et al. Immunological dysfunction persists for 8 370 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol. Published 371 online 2022. doi:10.1038/s41590-021-01113-x 372 Mainous AG, Rooks BJ, Wu V, Orlando FA. COVID-19 Post-acute Seguelae Among 26.

373 Adults: 12 Month Mortality Risk. Front Med. 2021;8. doi:10.3389/fmed.2021.778434 374 27. Rabe KF, Nair P, Brusselle G, et al. Efficacy and Safety of Dupilumab in Glucocorticoid-375 Dependent Severe Asthma. N Engl J Med. 2018;378(26):2475-2485. 376 doi:10.1056/NEJMoa1804093 377 28. Hamilton JD, Harel S, Swanson BN, et al. Dupilumab suppresses type 2 inflammatory 378 biomarkers across multiple atopic, allergic diseases. Clin Exp Allergy. 2021;51(7):915-379 931. doi:10.1111/cea.13954 380 29. Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte Chemoattractant Protein-1 381 (MCP-1): An Overview. J Interf Cytokine Res. 2009;29(6):313-326. 382 doi:10.1089/jir.2008.0027 383 Chen Y, Wang J, Liu C, et al. IP-10 and MCP-1 as biomarkers associated with disease 30. 384 severity of COVID-19. Mol Med. 2020;26(1). doi:10.1186/s10020-020-00230-x